Platelet aggregation inhibitors: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
Line 10: Line 10:


===Glycoprotein IIb/IIIa inhibitors===
===Glycoprotein IIb/IIIa inhibitors===
Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include eptifibatide, tirofiban, and the monoclonal antibody abciximab.
Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]] [[abciximab]] and  the small-molecule agents [[tirofiban]] and [[eptifibatid]].


===Thienopyridines===
===Thienopyridines===

Revision as of 09:37, 17 January 2010

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Platelet aggregation inhibitors, also called antiplatelet drugs, are "drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system."[1]

Classification

Adenosine diphosphate (ADP) blocker

This includes dipyrimadole.

Cyclooxygenase-1 blockers

Cyclooxygenase-1 blockers include aspirin.

Glycoprotein IIb/IIIa inhibitors

Inhibitors of the platelet glycoprotein GPIIb-IIIa complex (GPIs) include the monoclonal antibody abciximab and the small-molecule agents tirofiban and eptifibatid.

Thienopyridines

Thienopyridines include clopidogrel, ticlopidine, and the prodrug prasugrel.[2] They inhibit the ADP receptor.

References